Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying DiseaseRomain Lécuyer, Nahéma Issa, Fabrice Camou et al.|CHEST Journal|2024Cited by 49
Epidemiology and Clinical Impact of Respiratory Coinfections at Diagnosis of <i>Pneumocystis jirovecii</i> PneumoniaRomain Lécuyer, Nahéma Issa, Benoît Tessoulin et al.|The Journal of Infectious Diseases|2021Cited by 36
Immune checkpoint inhibitor-associated myocarditis: a novel risk scoreJohn R. Power, Anju Nohria, Richard K. Cheng et al.|European Heart Journal|2025Cited by 34
Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation RecipientsAntoine Lafarge, Élie Azoulay, Thibault Dupont et al.|American Journal of Respiratory and Critical Care Medicine|2024Cited by 16
Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysisCéline Eldani, E. Gérard, Marie Kostine et al.|Frontiers in Oncology|2024Cited by 14